Mesoblast Company Leadership
| MESO Stock | USD 16.89 1.41 7.70% |
Mesoblast employs about 81 people. The company is managed by 15 executives with a total tenure of roughly 189 years, averaging almost 12.0 years of service per executive, having 5.4 employees per reported executive. Analysis of Mesoblast's management performance can provide insight into the firm performance.
Mesoblast | Build AI portfolio with Mesoblast Stock |
Mesoblast's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Mesoblast's future performance. Based on our forecasts, it is anticipated that Mesoblast will maintain a workforce of about 110 employees by March 2026.Mesoblast Management Team Effectiveness
The company has return on total asset (ROA) of (0.0537) % which means that it has lost $0.0537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1895) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of February 2026, Return On Tangible Assets is likely to drop to -0.58. In addition to that, Return On Capital Employed is likely to drop to -0.09. At this time, Mesoblast's Non Currrent Assets Other are very stable compared to the past year. As of the 12th of February 2026, Asset Turnover is likely to grow to 0.05, while Total Assets are likely to drop about 596.4 M.As of the 12th of February 2026, Common Stock Shares Outstanding is likely to drop to about 69.5 M. In addition to that, Net Loss is likely to drop to about (77.4 M)Mesoblast maintains a total of 128.29 Million outstanding shares. Mesoblast secures 5.0 % of its outstanding shares held by insiders and 2.53 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 127.3 M | Current Value 127.3 M | Avarage Shares Outstanding 65.3 M | Quarterly Volatility 21.8 M |
Mesoblast Workforce Comparison
Mesoblast is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,155. Mesoblast holds roughly 81.0 in number of employees claiming about 2.57% of equities under Health Care industry.
Mesoblast Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Mesoblast Price Series Summation is a cross summation of Mesoblast price series and its benchmark/peer.
Mesoblast Notable Stakeholders
A Mesoblast stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mesoblast often face trade-offs trying to please all of them. Mesoblast's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mesoblast's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| LLB BCom | Joint Secretary | Profile | |
| Justin BS | Head Manufacturing | Profile | |
| LLB BSc | General Executive | Profile | |
| Marcelo Santoro | Chief Officer | Profile | |
| Roger BA | Head Disorders | Profile | |
| Fiona See | Senior Research | Profile | |
| MS MBA | Chief Officer | Profile | |
| BSc LLB | Gen Exec | Profile | |
| James OBrien | Chief Officer | Profile | |
| FACP FACRA | CEO, Founder | Profile | |
| Eric MD | Chief Director | Profile | |
| Andrew BCom | Interim Officer | Profile | |
| Paul BPHARM | Joint Secretary | Profile | |
| MBA MS | Head Partnering | Profile | |
| Dr BSc | Scientific Officer | Profile |
About Mesoblast Management Performance
The success or failure of an entity such as Mesoblast often depends on how effective the management is. Mesoblast management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mesoblast management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mesoblast management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.55) | (0.58) | |
| Return On Capital Employed | (0.08) | (0.09) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.15) | (0.16) |
Mesoblast Workforce Analysis
Traditionally, organizations such as Mesoblast use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mesoblast within its industry.Mesoblast Manpower Efficiency
Return on Mesoblast Manpower
| Revenue Per Employee | 212.3K | |
| Revenue Per Executive | 1.1M | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 6.8M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 6.8M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Will Biotechnology sector continue expanding? Could Mesoblast diversify its offerings? Factors like these will boost the valuation of Mesoblast. Expected growth trajectory for Mesoblast significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mesoblast data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.85) | Revenue Per Share | Quarterly Revenue Growth 4.586 | Return On Assets | Return On Equity |
Investors evaluate Mesoblast using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mesoblast's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mesoblast's market price to deviate significantly from intrinsic value.
Understanding that Mesoblast's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mesoblast represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mesoblast's market price signifies the transaction level at which participants voluntarily complete trades.